Bioporto A/s · OMXCOP:BIOPOR

Bioporto A/s — Q2 2020 Earnings Presentation

27 slides from Bioporto A/s's earnings presentation, Aug 19, 2020

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements. Words such as “believe”, “expect”, “may”, “plan”, “strategy”, “estimate”, “target” and similar expressions identify such forward-looking statements. Statements other than historical facts included in this presentation
Slide 3: Agenda
1 Highlights from Q2 2020 Agenda 2 Q2 2020 Financial Results 3 NGAL Regulatory Strategy & Status 4 NGAL and COVID-19 5 gRAD – A Development Platform 6 2020 Milestones 7 Appendix: About BioPorto 3
Slide 5: Highlights from Q2 2020
Highlights from Q2 2020 • Strong sales growth for The NGAL Test – product revenue nearly doubled in Q2 2020 vs. Q2 2019 • Enrollment begins in US pediatric clinical trial of The NGAL Test, submission expected in 2H 2020 • Collaboration with SDU to develop test for COVID-19 active virus based on gRAD
Slide 7: Strong continued growth in product sales of The NGAL Test in Q2 2020
Strong continued growth in product sales of The NGAL Test in Q2 2020 Revenue by Product Category (DKKm) +96% US NGAL Q2 2019 5,0 Q2 2020 3,8 Increase in revenue from RUO use of The NGAL Test in US from Q2 2019 to Q2 2020 2,4 ROW NGAL 1,4 0,6 1,1 +85% 0,2 0,1 Revenue from ROW product sales of NGAL EL
Slide 8: The NGAL Test sales up 81% YoY in 1H 2020
The NGAL Test sales up 81% YoY in 1H 2020 Driven by sales to new and existing customers Revenue by Product Category (DKKm) LTM NGAL Product Sales (DKKm) +68% NGAL 7,1 1H 2019 1H 2020 14 5,3 5,1 11 10 2,8 10 10 2,5 9 9 8 0,8 0,5 7 0,2 6 NGAL ELISA kits Antibodies Other products Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q
Slide 9: BioPorto Strengthens Financial Position
BioPorto Strengthens Financial Position Fully subscribed share issue in April 2020 • A total of 24,992,053 new shares offered in pre-emptive rights issue in March/April 2020 • Very strong interest in participating – binding commitments and guarantees for >70% of the offering • Fully subscribed offer
Slide 11: Regulatory Strategy for NGAL
Regulatory Strategy for NGAL Pediatrics Adults Additional Indications • Nephrotoxicity − Oncology − Cardiology 1 in 4 affected with AKI31 during hospitalization 1 in 5 adults affected with AKI − Diabetes (ICU) during a hospital episode of intensive care32 − Transplant − Autoimmune Predict AKI Risk i
Slide 12: NGAL 2020 Pediatric Study
Study overview NGAL 2020 Pediatric Study • Prospective trial to establish and validate the performance of The NGAL Test • Pediatric population (≥3 months to <22 years old), urine samples • Patients admitted to the ICU with cardiovascular or respiratory compromise, or who have had a bone marrow or so
Slide 14: AKI and COVID-19: Multifactorial Causes of Kidney Dysfunction
AKI and COVID-19 Multifactorial Causes of Kidney Dysfunction • Kidney involvement in hospitalized patients is frequent, ranging from mild dysfunction to progressive acute kidney injury (AKI) • Multiple dependent pathways in the setting of COVID-19 increase the risk of acute kidney injury • Systemic
Slide 16: Proprietary Platform: gRAD
BioPorto’s patented lateral flow development system Proprietary Platform: gRAD • BioPorto’s patented Generic Rapid Assay Device (gRAD) was developed in 2016 to enable rapid development of lateral flow tests • Features of gRAD include: – Optimized with two printed lines: a test line for biotinylated
Slide 17: Benefits of BioPorto's gRAD Solution
Benefits of BioPorto’s gRAD Solution Fast Versatile Easy Low Cost Scalable Short Flexible design No instruments, Simple format Design allows incubation time allows different fewer than 5 steps, with few rapid iteration <15 minutes sample types room temp stable components (days not weeks) and scale u
Slide 18: Platform for Product Development & Growth
gRAD Platform for Product Development & Growth NGALds Leveraging the gRAD platform, BioPorto is developing tests for NGAL as well as three emerging applications: COVIDds 1. NGALds: for outpatient assessment of kidney injury 2. Two COVID-19 assays: a viral diagnostic test and a gRAD serology-based te
Slide 19: NGALds for Near-Patient Testing
NGALds for Near-Patient Testing • NGALds is the first assay developed on the gRAD platform • CE Mark expected in November 2020 • A rapid lateral flow test to offer semi-quantitative urine NGAL results without complexity or instrumentation – idea for outpatient or low-resource settings • A sandwich l
Slide 20: Viral COVIDds
Unique opportunity to use gRAD technology Viral COVIDds Product Format Update & Next Steps • Indication: Screen patients suspected of • Antibody development & testing - ongoing COVID-19 infection for active virus • Antibody selection & optimization - ongoing • Semi-quantitative, rapid immunoassay de
Slide 22: Targeted 2020 Milestones
Clinical, regulatory and commercial Targeted 2020 Milestones • Finalize collection of data for the FDA application of The NGAL Test for pediatrics and submit application in the second half of 2020 • Collect supplementary data to support submission of an application for The NGAL Test in adults • Co-d
Slide 23: Financial Calendar 2020
Financial Calendar 2020 November 18, 2020 Q3 2020 Results Contact: Ole Larsen (CFO) ol@bioporto.com © Copyright BioPorto
Slide 25: About BioPorto
About BioPorto • Research assays ELISA Kits • Clinical diagnostics BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to • The NGAL Test transform novel research tools into clinically
Slide 26: Mission, Vision and Strategy
Mission, Vision and Strategy BioPorto helps healthcare providers improve patient management and outcomes with products that provide early and specific insights into significant clinical conditions. By 2025, we aspire to be one of the world’s leading companies in diagnostics for kidney health. Establ
Slide 27: Experienced International Management Team
BioPorto’s leadership Experienced International Management Team Peter Mørch Eriksen CEO CEO of BioPorto since July 2013 20+ years in medtech/life sciences, including CEO of Sense A/S and VP/GM of Medtronic Amy Winslow Ole Larsen Jan Kuhlmann President, Christopher Bird CFO COO BioPorto Diagnostics I

BioPorto — Q2 2020 Earnings Presentation on 6ix

Bioporto A/s — Q2 2020 Earnings Presentation

Slide 1: Interim Report, Q2 2020

Slide 2: Forward-Looking Statements

Slide 3: Agenda

Slide 4: Highlights from Q2 2020

Slide 5: Highlights from Q2 2020

Slide 6: Q2 2020 Financial Results

Slide 7: Strong continued growth in product sales of The NGAL Test in Q2 2020

Slide 8: The NGAL Test sales up 81% YoY in 1H 2020

Slide 9: BioPorto Strengthens Financial Position

Slide 10: NGAL Regulatory Strategy & Status

Slide 11: Regulatory Strategy for NGAL

Slide 12: NGAL 2020 Pediatric Study

Slide 13: NGAL & COVID-19

Slide 14: AKI and COVID-19: Multifactorial Causes of Kidney Dysfunction

Slide 15: BioPorto's gRAD: A Development Platform

Slide 16: Proprietary Platform: gRAD

Slide 17: Benefits of BioPorto's gRAD Solution

Slide 18: Platform for Product Development & Growth

Slide 19: NGALds for Near-Patient Testing

Slide 20: Viral COVIDds

Slide 21: 2020 Milestones

Slide 22: Targeted 2020 Milestones

Slide 23: Financial Calendar 2020

Slide 24: Appendix: About BioPorto

Slide 25: About BioPorto

Slide 26: Mission, Vision and Strategy

Slide 27: Experienced International Management Team